Novavax
NVAX
#5352
Rank
S$2.01 B
Marketcap
S$12.23
Share price
3.26%
Change (1 day)
46.61%
Change (1 year)

Novavax (NVAX) - Total liabilities

Total liabilities on the balance sheet as of March 2026 : S$1.52 Billion

According to Novavax's latest financial reports the company's total liabilities are S$1.52 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novavax - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31S$1.67 B-43.6%
2024-12-31S$2.96 B-10.59%
2023-12-31S$3.32 B-14.37%
2022-12-31S$3.87 B-2.04%
2021-12-31S$3.95 B213.27%
2020-12-31S$1.26 B161.13%
2019-12-31S$0.48 B-5.76%
2018-12-31S$0.51 B-5.01%
2017-12-31S$0.54 B-6.57%
2016-12-31S$0.57 B338.16%
2015-12-31S$0.13 B115.49%
2014-12-31S$61.28 M51.69%
2013-12-31S$40.4 M49.47%
2012-12-31S$27.03 M64.01%
2011-12-31S$16.48 M-18.99%
2010-12-31S$20.34 M-7.42%
2009-12-31S$21.97 M-50.65%
2008-12-31S$44.52 M9.63%
2007-12-31S$40.61 M-4.98%
2006-12-31S$42.74 M-26.08%
2005-12-31S$57.82 M-20.73%
2004-12-31S$72.94 M-10.96%
2003-12-31S$81.91 M-4.49%
2002-12-31S$85.77 M16.94%
2001-12-31S$73.34 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Novartis
NVS
S$102.47 B 6,601.21%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
S$150.89 B 9,767.16%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
S$85.77 B 5,509.05%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
S$77.48 B 4,966.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
S$2.15 B 40.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
S$70.83 M-95.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Agenus
AGEN
S$0.66 B-56.67%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
S$1.52 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
S$1.31 B-14.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
S$1.13 B-26.05%๐Ÿ‡บ๐Ÿ‡ธ USA